Bipolar Disorder - A Pipeline Analysis Report

Overview of the drug development pipeline for bipolar disorder

Bipolar disorder is also known as manic depression that causes extreme shifts in mood, energy, and activity levels. Elevated mood swings are called mania or hypomania, which differs based on the severity and presence of psychosis. Bipolar disorder is a long-lasting condition that can be categorized into bipolar I, bipolar II, and cyclothymia. This condition can be managed with a regular treatment. Insomnia, weight gain or loss, behavioral changes, and psychological imbalances are some of the symptoms witnessed in individuals with bipolar disorder. Technavio’s market research analysts have predicted that with the introduction of behavioral therapy, substance abuse treatment, and electroconvulsive therapy as some of the most promising approaches to treat bipolar disorder, the global bipolar disorder market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase III, pre-clinical, discover drug development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase I, phase II, and phase II/III development stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of bipolar disorder. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Amorsa Therapeutics
• KemPharm
• NeuroRx

Therapeutic assessment of the drug development pipeline for bipolar disorder by route of administration

• Oral
• Undisclosed

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for bipolar disorder by therapeutic modality

• Small molecules
• Undefined

According to this pipeline analysis report, the majority of the molecules that are currently in the drug development pipeline for bipolar disorder are being developed as small molecules. These molecules are chemically manufactured active substances that enter cells easily due to their low molecular weight of less than 900 Daltons.

Key questions answered in the report include

• What are the drug development molecules in the various development stages of bipolar disorder?
• What are the companies that are currently involved in the development of bipolar disorder for bipolar disorder?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.